膜杰作
Star Staining
分子别名（Synonym）
IL-5,TRF,IL5,Interleukin-5
表达区间及表达系统（Source）
Cynomolgus IL-5, His Tag (IL5-C52H3) is expressed from human 293 cells (HEK293). It contains AA Ile 20 - Ser 134 (Accession # A0A2K5U1E7-1).
Predicted N-terminus: His
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 15.0 kDa. The protein migrates as 19-23 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Cynomolgus IL-5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
活性（Bioactivity）-ELISA
Immobilized Cynomolgus IL-5, His Tag (Cat. No. IL5-C52H3) at 5 μg/mL (100 μL/well) can bind Human IL-5 R alpha, Fc Tag (Cat. No. ILA-H5269) with a linear range of 1-39 ng/mL (QC tested).
Protocol
背景（Background）
Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.
